Xia Xiao

Investor Relations

2024 - Current

Strategy Director

2021 - 2023

- Collaborated with the CEO, VP and other key stakeholders to develop and implement the company’s strategy, business development, and led the company’s fund raising and investor relation practice - Built and led the PCR business unit

Investment Professional

2019 - 2021

- Sourced, evaluated, and negotiated investment terms for deals across multiple sectors and stages - Selected portfolios: 1) Pre-A investment in Onek Drug (Pharmaceutical distribution B2B platform); 2) Angel investment in AliveX Biotech (AI + immunity platform) - Selected portfolio management: Tezign (Digital creative content solutions for enterprises), Points Technology (Privacy computing), Flexport (The OS of global logistics)

Research Analyst

2017 - 2018

- Performed comprehensive research utilizing both top-down and bottom-up approaches to inform global TMT investment decisions and strategy - Facilitated the establishment of China-US Industrial Cooperation Partnership Fund between CIC and Goldman Sachs PIA

Research Analyst

2014 - 2017

TMT: Technology Hardware TMT Sector Research: Technology Equipment and Hardware; Electronic Component in both A share and H share markets

Summer Research Associate, Equity Research

2013 - 2013

China Bank Research

Summer Intern, Public Equity Investment

2012 - 2012

Summer Resesrch Associate, Equity Research

2012 - 2012

Transportation Sector in A and H-share market